Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Sarcoma 2Vulvar Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 9Gemcitabine 9Cyclophosphamide 8Radiotherapy 7Carboplatin 7Paclitaxel 6Cisplatin 6Trastuzumab 5Irinotecan 5Doxorubicin 5Docetaxel 5Peripheral Blood Stem Cell Transplantation 4Filgrastim 4Capecitabine 4poly ICLC 3pazopanib 3liposomal doxorubicin 3durvalumab 3atezolizumab 3Therapeutics 3Taxes 3Surveys and Questionnaires 3Radiation 3Polymerase Chain Reaction 3Oncolytic Virotherapy 3Letrozole 3Injections 3Fulvestrant 3Fluorodeoxyglucose F18 3Flow Cytometry 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × tivozanib × Sarcoma × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡